11A5

**11A5** is an investigational monoclonal antibody targeting alpha-synuclein, a protein whose aggregation forms Lewy bodies in neurodegenerative diseases like Parkinson's disease and dementia with Lewy bodies. Developed as a potential disease-modifying therapy, it binds to specific conformational epitopes on aggregated or pathological alpha-synuclein to promote clearance and inhibit propagation between neurons, as demonstrated in structural studies and organotypic slice culture models showing inter-neuronal spreading inhibition. Primary indications focus on synucleinopathies, with preclinical evidence supporting its role in reducing alpha-synuclein pathology.